RecruitingNCT06169033
Radiomics of Intra-abdominal and Subcutaneous Adipose Tissue Predict the Efficacy of Bariatric Surgery (RISABS)
Sponsor
China-Japan Friendship Hospital
Enrollment
800 participants
Start Date
Jan 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
Using radiomics of intra-abdominal and subcutaneous adipose tissue and clinical features to predict the weight loss efficacy and remission of type 2 diabetes mellitus after bariatric surgery.
Eligibility
Min Age: 16 YearsMax Age: 70 Years
Plain Language Summary
Simplified for easier understanding
This study is using specialized analysis of CT scan images of belly fat (called radiomics) to predict how well weight-loss surgery will work for patients with obesity and type 2 diabetes. Researchers want to find out if the type and location of fat in the body can help predict surgical outcomes.
**You may be eligible if...**
- You have a BMI greater than 27.5 kg/m²
- You have type 2 diabetes
- You are scheduled to have bariatric (weight-loss) surgery
**You may NOT be eligible if...**
- You do not have an abdominal CT scan available
- You are not having sleeve gastrectomy or Roux-en-Y gastric bypass surgery
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06169033
Related Trials
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
NCT011434543 locations
Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention
NCT019277831 location
Investigating the Impact of Obesity on Pubertal Development in Girls
NCT025836461 location
Diabetes and Heart Disease Risk in Blacks
NCT000018531 location
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
NCT0728497932 locations